Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P.

EBioMedicine. 2016 May;7:85-93. doi: 10.1016/j.ebiom.2016.03.047. Epub 2016 Apr 7.

2.

Tolerance of Phellodendron amurense bark extract (Nexrutine®) in patients with human prostate cancer.

Swanson GP, Jones WE 3rd, Ha CS, Jenkins CA, Kumar AP, Basler J.

Phytother Res. 2015 Jan;29(1):40-2. doi: 10.1002/ptr.5221. Epub 2014 Sep 9.

3.

Synthesis of substituted [8]cycloparaphenylenes by [2 + 2 + 2] cycloaddition.

Tran-Van AF, Huxol E, Basler JM, Neuburger M, Adjizian JJ, Ewels CP, Wegner HA.

Org Lett. 2014 Mar 21;16(6):1594-7. doi: 10.1021/ol500194s. Epub 2014 Mar 5.

PMID:
24597661
4.

Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis.

Hilton WM, Lotan Y, Parekh DJ, Basler JW, Svatek RS.

BJU Int. 2013 Jun;111(7):1054-60. doi: 10.1111/j.1464-410X.2012.11499.x. Epub 2012 Nov 21.

5.

High-grade prostate cancer: favorable results in the modern era regardless of initial treatment.

Ramahi EH, Swanson GP, Jackson MW, Du F, Basler JW.

ISRN Oncol. 2012;2012:596029. doi: 10.5402/2012/596029. Epub 2012 Jan 31.

6.

Socioeconomic disparities in prostate cancer mortality.

Basler JW.

South Med J. 2011 Aug;104(8):560. doi: 10.1097/SMJ.0b013e318224296b. No abstract available.

PMID:
21886063
7.

Prognostic factors for failure after prostatectomy.

Swanson GP, Basler JW.

J Cancer. 2010 Dec 7;2:1-19.

8.

Intraductal carcinoma of the prostate in the ejaculatory duct.

Sanchez-Salazar AJ, Basler JW, Nicolas MM.

Int J Surg Pathol. 2010 Aug;18(4):298-9. doi: 10.1177/1066896910364534. Epub 2010 May 5.

PMID:
20444733
9.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group..

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

10.

Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer.

Montgomery B, Lavori P, Garzotto M, Lee K, Brophy M, Thaneemit-Chen S, Kelly W, Basler J, Ringer R, Yu W, Whittemore A, Lin DW.

Urology. 2008 Sep;72(3):474-80. doi: 10.1016/j.urology.2008.02.050. Epub 2008 Apr 14. Review. No abstract available.

PMID:
18407333
11.

Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.

Bruder JM, Ma JZ, Wing N, Basler J, Katselnik D.

J Clin Densitom. 2006 Oct-Dec;9(4):431-7. Epub 2006 Sep 6.

PMID:
17097529
12.

Evaluation of mechanical bowel preparation methods in urinary diversion surgery.

Morey AF, Evans LA, McDonough RC 3rd, Park AM, Sexton WJ, Basler JW, Santucci RA, Amling CL, O'Reilly KJ.

Can J Urol. 2006 Oct;13(5):3250-4.

PMID:
17076946
13.

Metastatic prostate cancer-does treatment of the primary tumor matter?

Swanson G, Thompson I, Basler J, Crawford ED.

J Urol. 2006 Oct;176(4 Pt 1):1292-8. Review.

PMID:
16952615
14.

Current status of lymph node-positive prostate cancer: Incidence and predictors of outcome.

Swanson GP, Thompson IM, Basler J.

Cancer. 2006 Aug 1;107(3):439-50. Review.

15.

Efficacy of taxotere in the post-prostatectomy setting.

Basler JW.

Curr Urol Rep. 2006 May;7(3):165. No abstract available.

PMID:
16770854
16.

Treatment options in lymph node-positive prostate cancer.

Swanson GP, Thompson IM, Basler J.

Cancer. 2006 Jun 15;106(12):2531-9. Review.

17.

Dealing with non-cancerous findings on prostate biopsy.

Brand TC, Thibault GP, Basler JW.

Curr Urol Rep. 2006 May;7(3):186-92. Review.

PMID:
16630522
18.

Prostate cancer detection strategies.

Brand TC, Hernandez J, Canby-Hagino ED, Basler JW, Thompson IM.

Curr Urol Rep. 2006 May;7(3):181-5. Review.

PMID:
16630521
19.

Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.

Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2178-84.

20.

Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT).

Alderson RF, Toki BE, Roberge M, Geng W, Basler J, Chin R, Liu A, Ueda R, Hodges D, Escandon E, Chen T, Kanavarioti T, Babé L, Senter PD, Fox JA, Schellenberger V.

Bioconjug Chem. 2006 Mar-Apr;17(2):410-8.

PMID:
16536473

Supplemental Content

Loading ...
Support Center